Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
This article was originally published in The Pink Sheet Daily
Pfizer addresses investor concerns over the $68 billion mega merger at a follow up meeting Jan. 27.
You may also be interested in...
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.
Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.